Latest Breaking News On - Prnewswire synaptogenix inc - Page 1 : comparemela.com

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

NEW YORK, April 24, 2024 /PRNewswire/ Synaptogenix, Inc. , an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice.

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

Bryostatin-1 benefits in severe Alzheimer s disease patients were statistically significant with respect to placebo at p

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

/PRNewswire/ Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for.